Avalon Blogging Capital Technology 
Xconomy
SEPTEMBER 27, 2016
San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. Bregua Corp.,
socalTECH
JANUARY 18, 2011
and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
AUGUST 17, 2016
and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego.
Xconomy
JULY 19, 2016
Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.
Xconomy
JULY 10, 2016
It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. In 1998, Nelsen recalled, “People thought we were crazy” to apply optics to genotyping when Affymetrix and its solid phase arrays represented the dominant technology at the time. They had a lot of fun.”.
Xconomy
OCTOBER 30, 2016
Downtown Works is a co-working space for technology startups that opened last month in a completely renovated office building at the corner of India and West B streets. The co-working space occupies the top floor and mezzanine of the building, and includes shared desks, offices, conference rooms, kitchen, and rooftop deck. It’s really cool.”.
Xconomy
DECEMBER 7, 2018
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.
Expert insights. Personalized for you.
40 
Let's personalize your content